Gene therapy company Krystal Biotech Inc (NASDAQ:KRYS) on Tuesday announced its plans to launch USD100m common stock in underwritten public offering .
The company plans to provide the underwriters with a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering.
Net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments, may be used by the company to complete the ongoing pivotal trial of B-VEC for DEB, advance KB105 in TGM1-deficient icthyosis, develop KB104 for Netherton syndrome and KB407 for cystic fibrosis, accelerate the emerging respiratory pipeline, complete a good manufacturing practices certified manufacturing facility, working capital, general corporate purposes, research and development expenses as well as capital expenditures.
Subject to market and other conditions, there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, Cowen and Evercore ISI are acting as joint book-running managers for the offering.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera